FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 941 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 5th Grader Follows His Gut By Calling 911 On School Bus... January 9, 2020 Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant July 14, 2023 Popular Fitness Blogger Maria Kang Removed Her Breast Implants Due To... August 15, 2019 Survey Shows Oncologists Underestimate How Many Cancer Patients Use Alternative Therapies June 16, 2021 Load more HOT NEWS High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers Breast Cancer Survivor And Teenage Son Hand-Sew Neck Pillows To Bring...
